CPC A61K 31/495 (2013.01) [A61K 9/08 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/32 (2013.01); A61K 47/38 (2013.01); A61K 47/40 (2013.01); A61K 9/0053 (2013.01)] | 16 Claims |
1. A pharmaceutical composition in the form of an aqueous suspension comprising:
a. temozolomide or a salt thereof;
b. at least one agent controlling the solid state of temozolomide in the suspension;
c. water; and
d. optionally at least one acid in a quantity so that the pH of the composition is below 5;
wherein:
a concentration of temozolomide is higher than 10 mg/ml; and
the agent controlling the solid state of temozolomide in the suspension is a compound selected from the group consisting of silica (silicon dioxide), colloidal silica, hydrophobic colloidal silica, fumed silica, and mesoporous silica,
and wherein an amount of said agent controlling the solid state of temozolomide in the suspension is between 0.05 and 10% w/v of the composition.
|